Bioequivalence Study of Two Formulations of Tablets Ramipril 10 mg in Healthy Volunteers Under Fasting Conditions

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is an open-labeled, randomized, two period, single-center, crossover, comparative study, where each participant will be randomly assigned to the reference (Tritace®, 10 mg tablets) or the test (Ramipril, 10 mg tablets) formulation in each period of study (sequences Test-Reference (TR) or Reference-Test (RT)), in order to evaluate if both formulations are bioequivalent
Epistemonikos ID: 49a5f256654c81c0c97ca6eecf69655c4f415155
First added on: May 13, 2024